- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe chronic plaque psoriasis; Severe psoriatic arthritis; Severe Crohn disease; Complex refractory fistulising Crohn disease; Moderate to severe ulcerative colitis
- Meeting Date: July 2026
Ustekinumab – July 2026
- Injection 45 mg in 0.5 mL vial
- Injection 45 mg in 0.5 mL single use pre-filled pen
- Injection 90 mg in 1 mL single use pre-filled pen
Public Summary Documents
Last updated
13 November 2026
